Unveiling 4 Analyst Insights On Celldex Therapeutics
Portfolio Pulse from Benzinga Insights
In the latest quarter, Celldex Therapeutics (NASDAQ:CLDX) received mixed analyst ratings, with an updated average 12-month price target of $79.25, reflecting a 10.07% increase from the previous target. The company, engaged in developing immunotherapy technologies, showed a significant revenue growth of 156.11% as of December 31, 2023, but struggles with profitability, indicated by a net margin of -1048.32%. Analysts from HC Wainwright & Co., Cantor Fitzgerald, and Guggenheim provided insights, with one raising the price target to $90.00.
May 07, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Celldex Therapeutics received mixed analyst ratings with an increased average price target of $79.25. The company's significant revenue growth contrasts with its profitability challenges.
The mixed analyst ratings with an increased price target suggest a positive outlook on Celldex Therapeutics' stock price in the short term, despite the company's profitability challenges. The substantial revenue growth indicates strong business performance, which could positively influence investor sentiment and stock price. However, the high net margin loss and below-average financial metrics like ROE and ROA highlight underlying challenges that might temper the stock's upward momentum.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100